Karyopharm Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our headquarters are located in Newton, Massachusetts, where we currently lease a total of 98,502 square feet of office and research space through September 30, 2025, which will be reduced to 52,224 square feet of solely office space from October 1, 2025 through September 30, 2030.
We also lease approximately 3,681 square feet of office space in Munich, Germany.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.